Clofarabine: a new treatment option for patients with acute myeloid leukemia.

Author(s): Larson ML, Venugopal P

Affiliation(s): Section of Hemtology, Rush University Medical Center, 1725 West Harrison, Suite 809, Chicago, IL 60612, USA. Melissa_L_Larson@rush.edu

Publication date & source: 2009-06, Expert Opin Pharmacother., 10(8):1353-7.

Publication type: Review

Clofarabine is a rationally designed, second-generation deoxyadenosine analog that incorporates characteristics of two other purine analogs, fludarabine and cladribine. It has shown efficacy in hematologic malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia and myelodysplastic syndrome. It has already been approved for use in pediatric acute lymphoblastic leukemia after two lines of previous therapy. Clinical trials have also shown clofarabine to have activity both as a single agent and in combination with other cytotoxic drugs in adult myeloid leukemia. This compound seems to have efficacy in older patients, as well as those with adverse cytogenetics.